KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Liabilities and Shareholders Equity (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $19.6 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 7.67% to $19.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $74.9 billion through Dec 2025, up 6.92% year-over-year, with the annual reading at $19.6 billion for FY2025, 7.67% up from the prior year.
  • Liabilities and Shareholders Equity hit $19.6 billion in Q4 2025 for Royalty Pharma, up from $19.3 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $19.6 billion in Q4 2025 to a low of $15.9 billion in Q3 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $17.4 billion across 5 years, with a median of $17.6 billion in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 10.28% in 2023 and later increased 13.79% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $17.5 billion in 2021, then dropped by 4.01% to $16.8 billion in 2022, then decreased by 2.57% to $16.4 billion in 2023, then increased by 11.24% to $18.2 billion in 2024, then increased by 7.67% to $19.6 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for RPRX at $19.6 billion in Q4 2025, $19.3 billion in Q3 2025, and $18.3 billion in Q2 2025.